

Digestive Diseases Research Seminar  
*Presented by Yale School of Medicine,  
Department of Internal Medicine, and Section of Digestive Diseases*

# SGLT2 inhibitors for the comanagement of cirrhosis and diabetes mellitus

Saad R. Saffo, MD

Fellow of Medicine, Department of Internal Medicine (Digestive Diseases)  
Yale School of Medicine

Tuesday, April 26, 2022  
5:00 - 6:00 pm

<https://zoom.us/j/95144307903?pwd=bTMYSFRrVkhQK0kxRmN5NHROcUFQQQT09>

Host: Tamar Taddei, MD

Course Directors: Yasuko Iwakiri, PhD and Joseph Lim, MD

To record your attendance to this activity, text the Activity Code (29445) to 203-442-9435.

**There is no corporate support for this activity. Accreditation:** The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Cirrhosis impacts over 600,000 patients in the United States. Approximately 10% of patients with compensated cirrhosis will develop decompensated disease each year, and this progression is associated with a decline in median survival from 12 years to 2 years. There are limited treatments aimed at reducing the risk for hepatic decompensation among high-risk individuals such as those with coexisting type II diabetes mellitus. This treatment gap represents a critical unmet need in the care of patients with cirrhosis that may potentially be overcome with emerging therapies such as sodium-glucose co-transporter 2 inhibitors. **Objectives:** Describe the clinical interplay between type II diabetes mellitus and cirrhosis; Characterize the mechanisms by which sodium-glucose co-transporter 2 inhibitors could impact pathways implicated in portal hypertension; Discuss preliminary data and future aims on the association between sodium-glucose cotransporter 2 inhibitors and clinical outcomes in patients with cirrhosis and type II diabetes mellitus. **Faculty Disclosures:** None of the faculty/planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**